Axi-cel

DRUG3 trials

Sponsors

University Medical Center Groningen, Ruijin Hospital, M.D. Anderson Cancer Center

Conditions

B Cell LymphomaCAR-T RetreatmentDLBCL - Diffuse Large B Cell LymphomaNHL

Phase 2

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

RecruitingNCT05641428

University Medical Center GroningenDLBCL - Diffuse Large B Cell Lymphoma, NHL

Start: 2022-10-18End: 2027-12-31Target: 300Updated: 2024-09-23

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

RecruitingNCT06213311

M.D. Anderson Cancer CenterB Cell Lymphoma

Start: 2024-05-07End: 2027-01-31Target: 40Updated: 2026-01-14

Unknown Phase

Axi-cel Retreatment in Relapsed/Refractory LBCL

Ruijin HospitalCAR-T Retreatment

Start: 2023-03-04End: 2024-12-31Target: 32Updated: 2023-04-05

Related Papers

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood2024-11-054 citations